Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis: a Multi-center Randomized Prospective Study

NCT05863364 is registered in ClinicalTrials.gov with Xin Zeng as lead sponsor.

NCT NCT05863364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05863364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis: a Multi-center Randomized Prospective Study
Lead sponsor
Xin Zeng
Phase
Not applicable
Overall status
Unknown status
Start date
August 18, 2023
Completion date
December 31, 2025
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

decompensated cirrhosis